Navigation Links
New CDC Guidelines for Prevention of Intravascular Catheter-Associated Infections Designate Chlorhexidine Gluconate-Impregnated Sponge as a Category 1B Recommendation Exclusively Based on Evidence Related to BIOPATCH® Protective Disk With CHG
Date:4/1/2011

SOMERVILLE, N.J., April 1, 2011 /PRNewswire/ -- Ethicon, Inc., announced today that the CDC has reviewed clinical data from patients treated with BIOPATCH® Protective Disk with CHG as part of its update to the 2002 guidelines for reducing risk of intravascular catheter-associated infections in the United States. In the new guidelines, use of a CHG sponge dressing is designated as a Category 1B recommendation. BIOPATCH® is the only CHG-impregnated sponge dressing clinically proven to reduce central line-associated bloodstream infections (CLABSIs) and the only CHG-impregnated product with an FDA-cleared indication for this use.

The CDC's 2011 Guidelines for the Prevention of Intravascular Catheter-Related Infections defines a recommendation classified as Category 1B as "strongly recommended for implementation and supported by some experimental, clinical, or epidemiologic studies and a strong theoretical rationale." BIOPATCH® Protective Disk with CHG, distributed by Ethicon, Inc., has been shown to reduce the risk of CLABSIs in controlled, randomized clinical trials involving more than 4,000 patients.

"The new guidelines reinforce the findings from multiple clinical studies that have shown that BIOPATCH® is proven safe and effective in reducing the risk of CRBSIs in patients with central venous or arterial catheters. No other CHG dressing product on the market has been clinically proven to reduce this risk, and we are very pleased that the Category 1B recommendation has been based on clinical evidence related only to BIOPATCH®," said Earl Adamy, director of BIOPATCH®  sales and marketing at Ethicon.

The guidelines indicate that patients should be treated with "a chlorhexidine-impregnated sponge dressing for temporary short-term catheters in patients older than 2 months of age, if the CLABSI rate is not decreasing despite adherence to basic prevention measures, including education and training, appropriate use of chlorhexidine for skin antisepsis, and MSB [maximal sterile barrier precautions]. Category IB." Guidelines also specify "no recommendation is made for other types of chlorhexidine dressings (Unresolved Issue)."

In the United States, approximately 250,000 CLABSIs are estimated to occur each year. CLABSIs are associated with high mortality rates (12-25%), and extended hospital stays, requiring patients to spend an estimated 9-12 additional days in a hospital. According to the CDC, the cost of treating a single episode of CLABSI can range from $34,508 - $56,000. The average cost of the BIOPATCH® Protective Disk with CHG product is approximately $6.

"Our skin provides very effective protection against infection, but when the skin barrier is broken and a catheter is inserted into vascular tissue, the risk of bacteria migrating down the catheter itself or the catheter tract into the bloodstream increases significantly. BIOPATCH® has a unique proprietary design that allows for 360-degree contact with the skin and continuous delivery of CHG around the site of catheter insertion," said William Jarvis, MD, former acting director of the CDC's Hospital Infections Program and the former assistant chief of the National Nosocomial Infections Surveillance (NNIS) system.*

The safety and effectiveness of BIOPATCH® have not been established for children less than 16 years of age. The protective disk is not to be used on premature infants or on patients with a known sensitivity to CHG.

BIOPATCH® is marketed by Ethicon, Inc., a trusted, worldwide leader in surgical care. For over a century, Ethicon has continuously introduced innovations for wound closure, general surgery, wound management, women's health and urology and aesthetic medicine that fulfill the Company's vision: restoration of body and of life. For more information visit www.ethicon.com.

* Paid consultant to Ethicon, Inc.

Media Contact:
Bill Berry
Berry & Company
212-253-8881
bberry@berrypr.com


'/>"/>
SOURCE Ethicon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Genesis Biopharma Expresses Support for FDA Codevelopment Guidelines
2. Health Robotics i.v.STATION Certified as the Only Robot to Comply with Security Guidelines for Controlled Substances
3. Adventus Group Issues Guidelines Surrounding Use of Zero Valent Iron with Emulsified Vegetable Oil
4. ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ
5. Physician's Organization Makes History by Publishing U.S.'s First Adult Stem Cell Guidelines (ASCTA Drives Safe Stem Cell Practices)
6. FRC: NIH Stem Cell Guidelines Reflect Poor Science, Ignore Real Hope for Patients
7. International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia"
8. The International Society for Stem Cell Research Releases New Guidelines to Shape Future of Stem Cell Therapy
9. British School Kids With Diabetes Gain First Time Freedom From Injections With New Insulin Pump Guidelines
10. Soligenix Receives FDA Orphan Drug Designation for RiVax™ for the Prevention of Ricin Intoxication
11. HumanTouch Expands Services to the Centers for Disease Control and Prevention as a Prime Contract Holder as Part of $1.0 Billion Contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and ... rebranding initiative announced today. The bold new look is part of a transformation ... moves into a significant growth period. , It will also expand its service offering ...
(Date:10/10/2017)... -- International research firm Parks Associates announced today that ... TMA 2017 Annual Meeting , October 11 in Scottsdale, Arizona ... market and how smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase ... "The residential security market has experienced continued growth, ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings ... mechanism by which its ProCell stem cell therapy ... limb ischemia.  The Company, demonstrated that treatment with ... of limbs saved as compared to standard bone ... molecule HGF resulted in reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University ... adopting ground breaking 3D fingerprint minutiae recovery and matching technology, pushing ... for use in identification, crime investigation, immigration control, security of access ... ... A research team led by Dr Ajay ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
(Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
Breaking Biology News(10 mins):